A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis.
Christian A MerloTeja ThoratLisa J McGarryChristina V SciricaMaral DerSarkissianCatherine NguyenYuqian M GuAruna MuthukumarJoe HealyJaime L RubinM Alan BrookhartPublished in: Pulmonary therapy (2024)
IVA showed a durable clinical benefit by slowing the rate of lung function decline over 5 years. Results support a sustained and consistent impact of IVA on lung function trajectory in people with CF. Word count: 300 (limit: 300 words).